Enzymotec Ltd. (NASDAQ:ENZY) had its target price upped by stock analysts at Wells Fargo & Company from $9.50 to $12.00 in a report released on Monday. The brokerage currently has a “market perform” rating on the biotechnology company’s stock. Wells Fargo & Company’s price objective would indicate a potential upside of 1.69% from the company’s current price.

Several other research analysts also recently issued reports on ENZY. Jefferies Group LLC reiterated a “hold” rating and issued a $11.50 target price on shares of Enzymotec in a research note on Thursday, October 19th. Zacks Investment Research upgraded shares of Enzymotec from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 17th. Finally, ValuEngine upgraded shares of Enzymotec from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Four analysts have rated the stock with a hold rating, Enzymotec has an average rating of “Hold” and an average price target of $11.75.

Enzymotec (NASDAQ ENZY) traded up 5.33% during midday trading on Monday, hitting $11.85. 3,235,110 shares of the company were exchanged. The stock has a 50 day moving average of $11.27 and a 200 day moving average of $9.47. Enzymotec has a 1-year low of $5.20 and a 1-year high of $12.35. The firm’s market capitalization is $271.95 million.

Enzymotec (NASDAQ:ENZY) last posted its quarterly earnings data on Wednesday, August 16th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.15). Enzymotec had a negative return on equity of 3.88% and a negative net margin of 14.52%. The business had revenue of $13.00 million for the quarter, compared to the consensus estimate of $12.78 million. During the same period in the previous year, the firm earned $0.04 EPS. The company’s revenue was up 11.1% on a year-over-year basis. On average, equities analysts predict that Enzymotec will post $0.14 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Wells Fargo & Company Raises Enzymotec Ltd. (ENZY) Price Target to $12.00” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/30/wells-fargo-company-raises-enzymotec-ltd-enzy-price-target-to-12-00.html.

Several hedge funds and other institutional investors have recently modified their holdings of ENZY. Janus Henderson Group PLC bought a new position in shares of Enzymotec in the second quarter worth approximately $2,350,000. State Street Corp lifted its stake in shares of Enzymotec by 1.8% in the second quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock worth $169,000 after buying an additional 380 shares in the last quarter. Finally, Osborn Williams & Donohoe LLC bought a new position in shares of Enzymotec in the third quarter worth approximately $137,000. Hedge funds and other institutional investors own 27.20% of the company’s stock.

Enzymotec Company Profile

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.